Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. - Wikidata - awgldk - TriplyDB

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

http://www.wikidata.org/entity/Q46684151

about

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes Nintedanib in NSCLC: evidence to date and place in therapy VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Systemic and targeted therapies for early-stage lung cancer Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.ZEPHYR: failure of a "spring wind" in lung cancer.ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients.Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.Tyrosine kinase inhibitors in lung cancer.Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials Targeted therapies for lung cancer: clinical experience and novel agents Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review.Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer

P2860

Q26745422-9D547443-56FB-4D86-A5A3-FEB96D42B92B Q26745424-4671CA88-5064-4187-BC1C-D14DE19CFBD7 Q26770678-139A8C7B-9F89-4679-81D1-CD5AC1816DBF Q26775394-5C1306E1-3F91-41E0-8CE3-98D77683C317 Q26865490-1FD5FD12-DCDC-40F2-BE92-2B1916DB7DD1 Q26995204-78769E33-C194-423C-9C15-E52C1750D4BD Q27693185-9A9BEE0C-9D3A-4558-9F12-41D0740AFB2A Q28079328-E81038EC-3072-4ECD-A26A-D65D021AA926 Q28085104-60EAA462-DE76-47E3-87B2-168A084ECC42 Q28480930-C1605DBE-5E56-408D-B9F3-70ABAD982077 Q30356434-262F0513-ACED-4438-A527-DA363A10D95F Q33399254-945F7E84-CB84-4C5D-96C3-D2E946D4BF6C Q33418555-3D64A678-4EE3-490E-A81D-F2AA0414E209 Q33424852-D83F370C-C206-4C46-9BF6-3C5C54D4E11F Q33903078-4F283C1A-DB5D-4CB3-AC12-A8C323D3EE8A Q34316070-A3B52DF5-64E9-4DCB-8BF2-D2F06CA3926E Q34359274-E436016A-2F83-49F3-BD2C-7F89FBF9A550 Q34826532-F4C9B420-54E1-4214-AE7A-C1A6796AE7EE Q35168766-36E6C754-4A7B-416E-8406-46CC0A45C3A6 Q35187896-69DB1A3F-80E1-4A65-807F-F957713B5EA2 Q35200470-CB4AB410-95CD-4668-90FC-92859985ED66 Q35200483-E5B58895-95F6-4D51-ACD5-EE4388EF7A06 Q35346839-D0FD1D82-01C8-44CD-BB81-935E5578FE2F Q35545693-50917C76-7D75-45B8-B5A8-D1663A1E48F9 Q35632548-894BF2EB-FB30-440F-AEC5-E1E7F59CDD86 Q35649624-56F07DB8-ABEC-42C2-B496-79F2AD2C974F Q35677270-8459DBE8-A816-4BAD-812E-B1495361E54E Q35908430-289EA833-B5B5-4643-AD0C-78650972CD75 Q35966757-4DB9A767-28CF-4807-8B01-CEC02C1C2079 Q36037036-09269790-40E5-4F76-9F5A-469061F600D0 Q36054970-2EB7BA11-4F90-4A26-A0DD-BD5A3A42740F Q36301449-0B68EE9B-7DBF-43B4-82A8-1FA31E629F9A Q36630478-6D52D841-96AA-4596-83CB-29C8EE2E360F Q36729895-A21723B8-C29E-4650-94AB-0300D62DFA0F Q36738376-8355A2C3-A66D-48CD-8FD7-1586797A6C7C Q36811479-B9A4914B-8EDA-4EE8-A4E8-37054828FE64 Q36859958-831EF8F4-EC12-4A0A-A3AA-6F7FCDD3D6E8 Q36996220-73DC81F7-129E-4144-82D2-FB2C82A15525 Q37042424-35B7FDDD-C866-4041-AE1F-F90E5FFE4307 Q37246286-0B9F1DC0-8BCC-49E3-B3DD-38E1BCC0B1C0

P2860

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

http://www.wikidata.org/entity/Q46684151

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Vandetanib plus pemetrexed for ...... double-blind phase III trial.

@en

Vandetanib plus pemetrexed for ...... double-blind phase III trial.

@nl

type

label

Vandetanib plus pemetrexed for ...... double-blind phase III trial.

@en

Vandetanib plus pemetrexed for ...... double-blind phase III trial.

@nl

prefLabel

Vandetanib plus pemetrexed for ...... double-blind phase III trial.

@en

Vandetanib plus pemetrexed for ...... double-blind phase III trial.

@nl

P1433

Q46684151-A440FD79-2CC9-470F-8932-C64BBFF54650

P1476

Q46684151-A3141450-AA76-419B-9CEC-F300BA1963BF

P2093

Q46684151-0DBDB6F9-D3F1-4B4A-90FC-31D1D00B726A

Q46684151-1635D97A-687B-477B-B763-50B842B593A5

Q46684151-2C743DA0-4DEA-4F07-B83F-0C8BA5929925

Q46684151-62D030DE-1F05-4E4B-9EF5-1D8C01D3D05B

Q46684151-64F1DC1E-36C9-43B4-AB8B-13BFA9191323

Q46684151-6E048063-8EC5-4551-9746-CD145B301A5C

Q46684151-7B386C97-AFB7-4372-BD5E-0129BBA3532C

Q46684151-7BF1C2B7-E383-4318-97B2-37F13562C3FE

Q46684151-84C315C3-34ED-4BB0-BEC0-E4096B0B2B33

Q46684151-8C651D3E-8E41-442A-A60F-2F247DE2D03D

P304

Q46684151-E9AFCAF4-9C25-4D93-8DEF-1C49FA3DE760

P31

Q46684151-4DA6226C-56EC-46F0-8B1F-E1DBE31E3FAF

P356

Q46684151-9E7CA03D-9732-4B9E-B0DD-AFED4619E05C

P407

Q46684151-6B7A74C5-F9D9-46BC-8F25-1A6B5EE7F028

P433

Q46684151-8E2C1558-FA82-4163-8CB2-AA788F6BA7C3

P478

Q46684151-1EC0CFD3-0908-42AD-9149-C984B21CEF2B

P50

Q46684151-E3AB7CE9-BFA4-4EF9-B829-489F576A83BA

P577

Q46684151-E7BD1175-3E7E-47A4-A749-E60DFB57BAE9

P698

Q46684151-6C01ABFF-D36A-4101-AEFF-5FCB094571DB

P921

Q46684151-8F7B8CAE-55C3-4A45-9756-87E1222D4A39

P356

JCO.2010.29.5717

P1433

Journal of Clinical Oncology

P1476

Vandetanib plus pemetrexed for ...... double-blind phase III trial.

@en

P2093

Chih-Hsin Yang

http://www.w3.org/2001/XMLSchema#string

Filippo de Marinis

http://www.w3.org/2001/XMLSchema#string

Jessica Read

http://www.w3.org/2001/XMLSchema#string

Johan F Vansteenkiste

http://www.w3.org/2001/XMLSchema#string

Johann Raats

http://www.w3.org/2001/XMLSchema#string

Jürgen Wolf

http://www.w3.org/2001/XMLSchema#string

Maya Gottfried

http://www.w3.org/2001/XMLSchema#string

Peter Langmuir

http://www.w3.org/2001/XMLSchema#string

Raymond P Abratt

http://www.w3.org/2001/XMLSchema#string

Richard H de Boer

http://www.w3.org/2001/XMLSchema#string

P304

1067-1074

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.29.5717

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Fiona Blackhall

P577

2011-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21282537

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial